论文部分内容阅读
目的:评估他达拉非在治疗经尿道前列腺切除术(TURP)后勃起功能障碍(ED)的疗效。方法:113例TURP术后的ED患者接受为期3个月的希爱力(商品名他达拉非)治疗,治疗后随访6个月。在治疗前后及随访6个月后记录各组患者IIEF-5评分及患者性生活日记中插入和保持勃起的成功率并比较研究。结果:患者IIEF-5评分治疗前为(9.83±3.96)分,治疗后为(20.23±3.25)分,随访6个月后为(17.28±3.03)分,差异均有统计学意义(P<0.05)。药物治疗后,患者性生活日记中插入和完成性交的成功率分别从治疗前的44.8%和7.5%提高至治疗后的81.7%和63.2%。结论:他达拉非可以作为治疗TURP术后ED的一线用药。
PURPOSE: To evaluate the efficacy of tadalafil in the treatment of erectile dysfunction (ED) after transurethral resection of the prostate (TURP). Methods: A total of 113 ED patients undergoing TURP were treated with Cilazapril (trade name Tadalafil) for 3 months. The patients were followed up for 6 months. Before and after treatment and after 6 months of follow-up, the success rate of inserting and maintaining erection in IIEF-5 scores and diary of sex life of patients in each group was recorded and compared. Results: The score of IIEF-5 was (9.83 ± 3.96) before treatment and (20.23 ± 3.25) after treatment and (17.28 ± 3.03) after 6 months of follow-up. The difference was statistically significant (P <0.05 ). After drug treatment, the success rate of inserting and completing sexual intercourse in the sex life diaries increased from 44.8% and 7.5% before treatment to 81.7% and 63.2% after treatment, respectively. Conclusion: Tadalafil can be used as a first-line treatment for ED after TURP.